8-K: Bio-Path Holdings Announces Positive Interim Phase 2 Data for Prexigebersen in Acute Myeloid Leukemia Treatment

Bio-Path Holdings presented positive interim results from its Phase 2 study of prexigebersen in combination with other drugs for acute myeloid leukemia, showing significant clinical improvement and a tolerable safety profile.

Summary

• Bio-Path Holdings presented interim results from its Phase 2 study of prexigebersen (BP1001) in combination with decitabine and venetoclax for the treatment of acute myeloid leukemia (AML).
• The study included two cohorts: newly diagnosed AML patients and relapsed/refractory AML patients.
• In the newly diagnosed cohort, 75% of evaluable patients achieved complete remission (CR), CR with partial recovery of peripheral blood counts (CRh), or CR with incomplete hematologic recovery (CRi).
• In the relapsed/refractory cohort, 55% of evaluable patients achieved CR/CRi/CRh.
• The treatment was generally well-tolerated, with adverse events consistent with those expected from the other drugs and AML itself.
• The company plans to continue enrollment, aiming for up to 98 evaluable patients in the newly diagnosed cohort and 54 in the relapsed/refractory cohort.

Sentiment

Score: 8

Explanation: The document presents very positive interim results from a Phase 2 clinical trial, with high remission rates and a tolerable safety profile. The company's management is optimistic, and the data was selected for presentation at a major conference. However, the need for further trials and the risk of needing to raise capital temper the overall sentiment slightly.

Positives

• The interim results show a high rate of complete remission in both newly diagnosed and relapsed/refractory AML patients.
• The combination therapy appears to be well-tolerated, with manageable side effects.
• The data was selected for oral presentation at the prestigious ASCO Annual Meeting, highlighting the quality of the results.
• The study is ongoing, with plans to expand enrollment, indicating confidence in the treatment's potential.

Negatives

• The study is still in Phase 2, and further trials are needed to confirm these results.
• The adverse events, while expected, included fatigue, anemia, and neutropenia, which can be significant for patients.
• The study included a relatively small number of evaluable patients, which may limit the generalizability of the findings.

Risks

• The company's ability to raise additional capital is crucial for continued operations and clinical development.
• Clinical trial results may not be consistent in later stages with larger patient populations.
• There are risks associated with the maintenance of intellectual property rights and patent protection.
• Global pandemics, such as COVID-19, can impact the company's operations and clinical trials.

Future Outlook

Bio-Path expects to continue enrollment of up to 98 and 54 evaluable patients for Cohorts 1 and 2, respectively.

Management Comments

• We were honored to have our data selected for oral presentation at ASCO as it underscores not only the quality of our data, but also highlights the continued unmet need for these most vulnerable cancer patients, said Peter Nielsen, Chief Executive Officer of Bio-Path.
• We continue to advance this important study confident that prexigebersen can make a difference in the lives of these patients for whom there are limited treatment options.

Industry Context

The announcement is significant in the context of the ongoing need for effective treatments for acute myeloid leukemia, a challenging and often fatal blood cancer. The positive results suggest that Bio-Path's approach could offer a new option for patients with limited treatment choices.

Comparison to Industry Standards

• The complete remission rates of 75% in newly diagnosed patients and 55% in relapsed/refractory patients are promising when compared to standard treatments for AML.
• For newly diagnosed AML, standard induction chemotherapy regimens typically achieve complete remission rates of 60-80%, but these rates are often lower in older patients with adverse-risk disease, which is the patient population in this study.
• In relapsed/refractory AML, complete remission rates with standard salvage therapies are often much lower, typically ranging from 20-40%, making the 55% rate in this study particularly noteworthy.
• Companies like AbbVie and Genentech have developed venetoclax, which is part of the combination therapy used in this study, and the results suggest that the addition of prexigebersen may enhance the efficacy of venetoclax-based regimens.
• Other companies such as Agios Pharmaceuticals and Jazz Pharmaceuticals are also developing novel therapies for AML, and the results from Bio-Path will be closely watched by the industry.

Stakeholder Impact

• Shareholders may view the positive clinical trial results favorably, potentially increasing the company's stock value.
• Patients with AML may benefit from a new treatment option with promising efficacy.
• Employees of Bio-Path may be encouraged by the progress of the company's lead product candidate.
• The results may attract potential partners or investors to the company.

Next Steps

• Bio-Path plans to continue enrollment in the Phase 2 study, aiming for up to 98 evaluable patients in Cohort 1 and 54 in Cohort 2.
• The company will likely continue to analyze the data and prepare for future clinical trials.

Key Dates

Keywords

Acute Myeloid Leukemia, AML, Prexigebersen, BP1001, Decitabine, Venetoclax, Cancer Treatment, Clinical Trial, Phase 2 Study, Oncology, Biotechnology